GUANZE MEDICAL(02427.HK)香港發售股份獲超額認購14.23倍 發售價定為每股0.53港元
格隆匯12月28日丨GUANZE MEDICAL(02427.HK)發佈公吿,公司全球發售約1.93億股股份,其中中國香港發售股份1928.5萬股,國際發售股份約1.74億股;發售價已釐定為每股發售股份0.53港元,每手買賣單位5000股;西證國際為獨家保薦人;預期股份將於2022年12月29日於聯交所主板掛牌上市。
根據香港公開發售初步提呈發售的香港發售股份獲適度超額認購。公司已接獲合共4492份有效申請,相當於香港公開發售初步可供認購香港發售股份總數約14.23倍。根據國際發售初步提呈發售的發售股份獲適度超額認購,相當於根據國際發售初步可供認購的發售股份總數約1.2倍。基於最終發售價每股0.53港元,並根據基石投資協議,基石投資者已認購合共5632萬股,合共相當於經擴大已發行股本的5.9%及全球發售項下發售股份總數的29.2%。
根據發售價每股0.53港元,公司將自全球發售收取所得款項淨額估計約為7330萬港元。公司擬將所得款項淨額約46.4%用於延伸至山東省東部,以擴闊公司的客户基礎及進一步鞏固公司于山東省的市場地位;約37.3%將用於藉由策略性收購、取得醫療器械註冊證及將公司的軟硬件升級以加強公司醫學影像雲服務的供應;約2.7%將用於擴大公司的產品組合以橫向擴充公司的價值鏈;約2.5%將用於參與交易會、貿易展覽及會議,不斷推廣品牌及增加市場知名度;約2.5%將用於將公司的資訊科技系統升級;及剩餘約8.6%將用作額外營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.